drugset
drugset / Trial / NCT00110344

Research Study for Patients With Metastatic Renal Cell Carcinoma

NCT00110344 ↗

Phase 2 Terminated 1 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

This study has been designed to study patients diagnosed with advanced renal cell cancer with the primary tumor in place.

Timeline

Start
2005-11
Primary completion
2006-06
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 400 mg Oral

Indications

renal cell carcinoma